People | March 28, 2026
Shreehas Tambe appointed CEO & Managing Director of Biocon
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
This recognition demonstrate excellence in intellectual property (IP) value creation.
Subscribe To Our Newsletter & Stay Updated
